Breast cancer stem cells (CSCs) survive in inflammatory microenvironment, their survival are regulated by inflammatory cytokines and signaling pathways. Esculentoside A (EsA), a triterpene saponin derived from the root of Phytolacca esculenta, possesses antiinflammation effects; but whether it has anticancer activity is unknown. The purpose of this study is to test the inhibitory effect of EsA on the growth of breast CSCs and to elucidate its probable mechanisms of action. The proliferation inhibitory effect of EsA on breast CSCs in vitro were determined by cytotoxicity, mammosphere formation inhibition, apoptotic cell detection assays, and in vivo tumor growth inhibition experiment. The possible molecular mechanisms elucidating the inhibitory effect of EsA on breast CSC growth were examined with western blotting. EsA caused proliferation and mammosphere formation inhibition of breast CSCs; induced breast CSCs apoptotic death; suppressed the growth of tumors generated from breast CSCs significantly; the expressions of stemness proteins including ALDH1A1, Sox2, and Oct4 were downregulated; proapoptotic proteins, Bax and cleaved caspase-3 were upregulated, whereas the antiapoptotic protein Bcl-2 was reduced; IL-6/STAT3 pathway proteins including IL-6, phosphorylated STAT3 (Tyr705), and STAT3 (Ser727) were downregulated significantly in EsA-treated breast CSCs and tumor tissues. EsA inhibited breast CSC growth in vitro and in vivo through stemness attenuation and apoptosis induction by blocking IL-6/ STAT3 signaling pathway; it might serve as a novel candidate agent for human breast cancer treatment and/or prevention.
Breast cancer stem cells (CSCs) survive in inflammatory microenvironment, their survival are regulated by inflammatory cytokines and signaling pathways. Esculentoside A (EsA), a triterpene saponin derived from the root of Phytolacca esculenta, possesses antiinflammation effects; but whether it has anticancer activity is unknown. The purpose of this study is to test the inhibitory effect of EsA on the growth of breast CSCs and to elucidate its probable mechanisms of action. The proliferation inhibitory effect of EsA on breast CSCs in vitro were determined by cytotoxicity, mammosphere formation inhibition, apoptotic cell detection assays, and in vivo tumor growth inhibition experiment. The possible molecular mechanisms elucidating the inhibitory effect of EsA on breast CSC growth were examined with western blotting. EsA caused proliferation and mammosphere formation inhibition of breast CSCs; induced breast CSCs apoptotic death; suppressed the growth of tumors generated from breast CSCs significantly; the expressions of stemness proteins including ALDH1A1, Sox2, and Oct4 were downregulated; proapoptotic proteins, Bax and cleaved caspase-3 were upregulated, whereas the antiapoptotic protein Bcl-2 was reduced; IL-6/STAT3 pathway proteins including IL-6, phosphorylated STAT3 (Tyr705), and STAT3 (Ser727) were downregulated significantly in EsA-treated breast CSCs and tumor tissues. EsA inhibited breast CSC growth in vitro and in vivo through stemness attenuation and apoptosis induction by blocking IL-6/ STAT3 signaling pathway; it might serve as a novel candidate agent for human breast cancer treatment and/or prevention. 
| INTRODUCTION
Breast cancer is one of the most prevailing tumors and major causes of death from cancer in women globally, especially in developing countries (Kim, Yoo, & Goodman, 2015; Stubert, Dieterich, & Gerber, 2014; Torre et al., 2015) . Although much progress has been made in conventional and targeted therapies for breast cancer and improved patients' survival and life quality, there still exists lots of challenges in the treatment of patients with breast cancer, including radiochemotherapy resistance, tumor relapse, metastasis, and high patient mortality (Hu & Fu, 2012; Omene, Wu, & Frenkel, 2012; Wei & Lewis, 2015) . † Authors contributed equally to this work.
Accumulating scientific findings suggested that cancers, including breast cancer, contain cancer stem cells (CSCs). Breast CSCs have capacity of self-renewal and differentiation and are considered to be responsible for treatment resistance, recurrence, and metastasis of tumor after conventional therapeutics (Siddiqui et al., 2015) . The presence of breast CSCs may represent promising therapeutic targets (Fan et al., 2013; Wei & Lewis, 2015) . Pharmacological targeting CSCs, impairing CSC activity, could be invaluable as novel therapeutic modalities for breast cancer treatment and prevention (Ahmadipour et al., 2015; Bhuvanalakshmi et al., 2017; Omene et al., 2012) , but until now, there has been no effective drugs to kill CSCs for breast cancer treatment (Y. Xu et al., 2011) .
Phytochemicals have several advantages in targeting CSCs for breast cancer treatment and prevention, which can be developed as new drugs for breast cancer eradication via rational drug design and screening approaches (Chowdhury et al., 2017; Dandawate, Padhye, Ahmad, & Sarkar, 2013; Siddiqui et al., 2015; Wu, Hong, Ho, & Yen, 2015) .
Esculentoside A (EsA) is a triterpene saponin derived from the root of a perennial herb, Phytolacca esculenta. EsA has activity in regulating immune response, cell proliferation and apoptosis, and possesses antiinflammation activity and protective potential of liver damage against acetaminophen toxicity in previous investigations (Hu et al., 2010; Ma et al., 2013; Wang et al., 2016; Zhang et al., 2014; Zhong et al., 2013) . EsA inhibited proinflammatory factors and inflammatory cytokine production in vitro and in vivo (Ma et al., 2013; Wang et al., 2016; Yang, Wang, Yu, Zhu, & Xu, 2015; Zhang et al., 2014; Zhong et al., 2013) ; EsA exerts antiinflammatory activity by targeting ribosomal protein S3a and impairing its signaling transduction (Li et al., 2018) . After EsA treatment, the production of inflammatory cytokines induced by lipopolysaccharide, such as tumor necrosis factor-α, interleukin-1, interleukin-6 (IL-6), nitric oxide, and nuclear factor-κB p65, was decreased significantly, which contributed to the strong antiinflammatory activity of EsA Ju, Zheng, Cao, Fang, & Wang, 1998; Yang, Chen, Yu, & Xu, 2017; Yang et al., 2015; Zhong et al., 2013) .
Breast CSCs take the responsibility for tumor occurrence, development, chemoradiotherapy resistance, tumor recurrence, and metastasis (Ahmadipour et al., 2015; Fan et al., 2013; Hu & Fu, 2012; Omene et al., 2012; Siddiqui et al., 2015; Wei & Lewis, 2015) ; CSCs are maintained in inflammatory microenvironment (Hinohara & Gotoh, 2010; Iliopoulos, Hirsch, Wang, & Struhl, 2011; Lin et al., 2013; Papi et al., 2012; Sanguinetti, Santini, Bonafè, Taffurelli, & Avenia, 2015) , hence, proinflammatory cytokines and microenvironment may promote survival and growth of CSCs, whereas antiinflammatory agents may suppress the growth of CSCs and improve the outcome of cancer therapeutics (Sanguinetti et al., 2015) .
Based on the survival microenvironment of breast CSCs and the antiinflammation activity of EsA, it could be hypothesized that EsA might have inhibition effect on tumor growth by impairing CSCs.
However, there is no report on the anticancer activity of EsA so far.
To examine this hypothesis, this experimental investigation was therefore designed to confirm whether EsA has anticancer activity against breast CSCs in vitro and in vivo and to elucidate its possible mechanism of anticancer capacity.
| MATERIALS AND METHODS

| EsA and reagents
EsA was obtained from Chengdu Herbpurify Co., LTD (Chengdu, China, purity ≥98%, HPLC). DMEM, DMEM/F12 media, and fetal bovine serum (FBS) were obtained from GIBCO/Invitrogen (Shanghai, China); Trypsin, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), DMSO, and other chemicals and reagents were purchased from Sigma-Aldrich (Shanghai, China).
| Cell lines and cell culture
Human normal mammary epithelial cell line (MCF-10A), human normal liver cell line (LO2), mouse breast cancer cell line (EMT6), and human breast cancer cells (MCF-7) were obtained from Shanghai Cell Biology Institute of Chinese Academy of Sciences (Shanghai, China). Adherent monolayer EMT6 and MCF-7 cells were cultured in DMEM supplemented with 10% FBS, penicillin (100 U/ml) and streptomycin (100 μg/ml) in a humidified atmosphere of 5% CO 2 at 37°C. Human breast CSCs (MCF-7M) were grown with serum free medium and characterized as reported previously (Lin et al., 2013 (Chen et al., 2012) ; the culture medium was changed once every 2 days until mammospheres were formed.
| Toluidine blue staining
Both adherent murine breast cancer cells (EMT6) and mammosphere cells (EMT6M) were stained with toluidine blue staining buffer (Cioce et al., 2010) . The light cells (LCs) and dark cells (DCs) in adherent murine breast cancer cells and mammosphere cells were observed and photographed with photocamera-equipped light microscope. The numbers of LCs and DCs in six fields of each sample were counted and analyzed. The experiment was repeated three times.
| Immunofluorescence staining ALDH1A1
The adherent murine breast cancer cells (EMT6) and EMT6 mammospheres were fixed in 4% paraformaldehyde for 15 min, permeated with 0.01% Triton X-100 for 5 min, and blocked with 1% Bovine Serum Albumin (BSA) in Phosphate Buffered Saline (PBS) for 30 min. The cells were then immuno-reacted to rabbit anti-ALDH1A1 antibody (Beijing Biosynthesis Biotechnology Co., Ltd., Beijing, China) in a humidified chamber overnight at 4°C; then, the adherent cells and the mammospheres were incubated with fluorescein isothiocyante (FITC) labeled goat anti-rabbit secondary antibody for 1 hr. After three times of PBS washing, the adherent cells and mammospheres were counterstained with DAPI, and the images were taken using a Leica DMI400B inverted fluorescence microscope linked to a DFC340FX camera (Leica Microsystems GmbH, Wetzlar, Germany).
| Western blotting
Both parental adherent EMT6 cells and EMT6 mammospheres were lyzed in RIPA buffer (Beyotime Institute of Biotechnology, Shanghai, China); the extracted proteins were electrophoresed on 12% SDS-PAGE, transferred onto a polyvinyl difluoride membrane, and blocked for 1 hr in 5% nonfat milk. The membranes were subsequently probed with following primary antibodies (Beijing Biosynthesis Biotechnology Co., Ltd., Beijing, China) overnight at 4°C. Rabbit anti-β-actin was diluted at 1:1,000; rabbit anti-ALDH1A1 (bs-10162R), rabbit antiSox2 (bs-0523R), and rabbit anti-Oct4 (bs-0830R) were diluted at 1:400 and followed by incubation with secondary goat anti-rabbit IgG-HRP (Zhongshan Goldenbridge Biotechnology Co., LTD, Beijing, China). The signal proteins were then visualized with the chemiluminescence system (Milipore Corporation, Billera, MA). Images were obtained with western blotting analysis system (Universal Hood II, Bio-Rad) and normalized to β-actin and semiquantified using the ChemiDocTM XRS (Bio-Rad). 
| In vivo tumorigenesis assay
| Mammosphere formation assay
The inhibitory effect of EsA on mammosphere formation of murine and human breast CSCs was determined by planting EMT6M and 
| AO/EB staining apoptotic cells
Both EMT-6M and MCF-7M cells were cultured in 96-well plates (3,000 cells/well), incubated overnight, and treated with 100, 150, 200 μg/ml of EsA for 48 hr. The plates were centrifuged for 5 min; l00 μl of AO/EB dye mix (100 μg/ml acridine orange and 100 μg/ml ethidium bromide) was added in each well to stain apoptotic cells (Ribble, Goldstein, Norris, & Shellman, 2005) ; the morphology of apoptotic cells were observed under fluorescence microscope, and more than 500 cells were counted. The experiment was performed three times independently.
| Annexin V-FITC/PI double staining assay
EsA-induced apoptotic cells were measured using the Annexin V- 
| Tumor growth inhibition test in vivo
Thirty-two 6-week-old female BALB/c mice were inoculated with murine breast CSCs (EMT6M) subcutaneously, 2 × 10 6 cells per mouse. After 1 week of inoculation, tumors generated in all inoculated mice (100%), when tumors reached about 100 mm 3 in size, the tumorbearing mice were divided into four groups randomly, eight mice were included in each. Three treatment group mice were given by gavage with 10, 20, and 40 mg/kg of EsA, five times a week for 6 weeks, respectively, and the control mice were administrated with equal volume of saline. In the experimental period, mice were weighted, and tumor volumes were measured and calculated using a standard formula (length × width 2 × 0.5) each week (Tsai et al., 2009) (bs-0523R), and Oct4 (bs-0830R); apoptotic proteins including Bcl-2 (bs-0032R), Bax (bs-4564R), and caspase-3 (bs-0081R); IL-6/STAT3
pathway proteins including IL-6 (bs-4587R), STAT3 (bs-20382R), pSTAT3 (Tyr705, bs-5526R), and pSTAT3 (Ser727, bs-3429R), were evaluated with western blot analysis as described above.
| Statistical analysis
All values are expressed as mean ± standard deviation (SD) and analyzed using analysis of variance, followed by Dunnett's test for respectively, the maximal inhibition of murine and human breast cancer cell and CSC growth (>90%) was obtained at 300 μg/ml.
| EsA inhibited mammosphere formation of murine and human breast CSCs
Untreated murine and human breast CSCs seeded at 100 cells per well generated 35.44 ± 5.1 and 39.56 ± 4.8 mammospheres, respectively.
Mammosphere formation potential was inhibited dose-dependently after 100, 150, and 200 μg/ml of EsA treatment (Figure 2g , p < 0.01) in both murine and human breast CSCs. analyses found that apoptotic cells in the untreated murine and human breast CSCs were 2.70 ± 1.40% and 1.90 ± 1.20%, respectively, after 100, 150, and 200 μg/ml of EsA treatment for 48 hr; the apoptotic cells in EMT6 CSCs treated with EsA were 7.9 ± 1.20%, 10.7 ± 1.60%, and 33.9 ± 3.20%, respectively; and 9.2 ± 1.31%, 11.3 ± 1.76%, and 20.2 ± 2.50% in EsA-treated MCF-7 CSCs, with no difference of necrotic cells (Figure 4a -d, p < 0.01).
| Apoptotic cells detected by AO/EB staining
| EsA suppressed breast CSC initiated tumor growth in vivo
The tumor growth inhibitory effect of EsA on breast cancer grew from EMT6M is shown in Figure 5 . resulted in the patients with breast cancer continue to die of the disease (Wei & Lewis, 2015) . Previous investigations implied that CSCs are the main cause of tumor recurrence and metastasis, as well as resistance to conventional treatment (Omene et al., 2012; Siddiqui et al., 2015) . Accordingly, targeting CSCs and inhibiting breast CSC growth has been regarded as a novel therapeutic strategy for breast cancer treatment and prevention (Ahmadipour et al., 2015; Jiang et al., 2016; Wei & Lewis, 2015) . Breast CSCs contributed to radiocheotherapy resistance, tumor recurrence, and metastasis of cancer, the phenotype and stemness of breast CSCs were regulated by inflammatory cytokines, such as IL-6 (Iliopoulos et al., 2011) , inflammatory microenvironment nourish the survival and growth of CSCs (Hinohara & Gotoh, 2010; Iliopoulos et al., 2011; Papi et al., 2012) .
EsA, a saponin purified from the roots of Phytolacca esculenta, processes potential antiinflammation activity in vitro and in vivo through suppression of a panel of proinflammation molecule production with less toxicity Dong et al., 2017; Ju et al., 1998; Ma et al., 2013; Wang et al., 2016; Yang et al., 2015; Yang et al., 2017; Zhang et al., 2014; Zhong et al., 2013) . Thus, it could be speculated that EsA might be a promising candidate for treatment and prevention of some cancers (Xiao et al., 2006) . However, there is no study about the anticancer activity of EsA reported up to now Dong et al., 2017; Ju et al., 1998; Li-Hua et al., 2017; Ma et al., 2013; Wang et al., 2016; Xiao et al., 2006; Yang et al., 2015; Yang et al., 2017; Zhang et al., 2014; Zhong et al., 2013) .
In this study, murine breast cancer cells (EMT6), breast CSCs (EMT6 mammosphere, EMT6M), human breast cancer cells (MCF-7), and breast CSCs (MCF-7 mammosphere, MCF-7M) were treated with EsA in vitro, the proliferation of murine and human breast cancer cells and CSCs was inhibited dose-dependently (Figure 2c -f, p < 0.01); and Dong et al., 2017; Ju et al., 1998; Ma et al., 2013; Wang et al., 2016; Yang et al., 2015; Yang et al., 2017; Zhang et al., 2014; Zhong et al., 2013) . The findings in this experimental study suggest that EsA has anticancer activity against breast cancer by suppression breast CSC growth both in vitro and in vivo.
To explain the possible mechanisms of the anticancer activity of EsA against breast CSCs in vitro and in vivo, the stemness, apoptotic proteins, and IL-6/STAT3 pathway-related protein expressions in EsA-treated breast CSCs and tumor tissues were analyzed with western blotting.
After EsA treatment, the expressions of stemness proteins including ALDH1A1, Sox2, and Oct4 were downregulated in both breast CSCs and tumor tissues significantly (Figures 6, 7 , 8a,b, p < 0.01).
Aldehyde dehydrogenase 1 (ALDH1) is a marker of breast CSCs, and its expression was relevant with poor prognosis of breast cancer patients (Kang et al., 2014) ; ALDH1+ breast CSCS may contribute to a more aggressive and metastasis phenotype of breast cancer (Kang et al., 2014; Kim, Jung, Ryu, & Lee, 2014; Zhong et al., 2014) ; ALDH1 activity inhibition may suppress tumorsphere formation and tumorigenesis (Kim et al., 2014; Young et al., 2015; Zhong et al., 2014) .
Sox2 is a transcription factor and an embryonic stem cell marker; it is involved in the carcinogenesis of breast cancer, tumor progression, metastases, and tamoxifen-resistance (Abd El-Maqsoud & Abd El-Rehim, 2014; Jung et al., 2014) . Downregulation of Sox2 expression decreased the cell number of breast CSCs and restored sensitivity to tamoxifen (Huang et al., 2014) . Oct4 is a critical transcription factor implicated in maintaining stemness, plays a pivotal role in maintaining the self-renewal and pluripotency for stem cells and breast cancer cells (Huang et al., 2014) , and maintains the survival of breast CSCs through inhibiting apoptosis . RNAi against Oct4 and Oct4 (Kim & Nam, 2011; Shen et al., 2014 ).
In the current experimental study, breast CSCs were treated with EsA in vitro and in vivo, the expressions of breast CSC marker, ALDH1A1 (Kang et al., 2014; Kim et al., 2014) and stemness-related transcription factors, Sox2, and Oct4 (Abd El-Maqsoud & Abd El-Rehim, 2014; Hu et al., 2008; Huang et al., 2014; Jung et al., 2014; Kim & Nam, 2011; Shen et al., 2014) were reduced dose-dependently, it is indicated that EsA has anticancer activity against breast cancer through attenuation of the stemness phenotype of CSCs.
CSCs survive by evasion of apoptosis, apoptosis signaling pathway inactivation also helps CSCs resist to most of cytotoxic anticancer drugs (Jung, Park, Lee, Seo, & Kang, 2011) . Two main pathways are involved and inactive in CSC apoptosis, the extrinsic or intrinsic apoptosis pathway. Antiapoptotic Bcl-2 family proteins were overexpressed in most of CSCs; reduction of Bcl-2 expression or augmentation of Bax expression can induce CSC apoptosis (Hu et al., 2008; Jung et al., 2011; Niu et al., 2015 ).
In the current experimental investigation, EsA-induced breast CSCs apoptotic death dose-dependently (Figures 3, 4 , p < 0.01). It increased Bax and cleaved caspase-3 protein expressions, decreased Bcl-2 protein expression significantly in EsA-treated breast CSCs in vitro and tumor tissues in vivo dose-dependently (Figures 6, 7, 8c, d, p < 0.05) . It was suggested that EsA might have effects on activating apoptosis pathway in breast CSCs, induces CSCs caspase-dependent intrinsic apoptosis (He, Zhou, Shen, Liao, & Cao, 2014; Zhang et al., 2015) .
Inflammatory cytokine IL-6 was associated with tumor progression, metastasis, treatment resistance, and poor clinical outcome for breast cancer patients (Lin, Gan, Han, Yao, & Min, 2015; Markkula, Simonsson, Ingvar, Rose, & Jernström, 2014) . It is a major activator of the signal transducer and activator of transcription 3 (STAT3) signaling pathway (Sağlam, Ünal, Subaşı, Ulukaya, & Karaöz, 2015) and plays a pivotal role in regulation of the phenotype and stemness of breast CSCs (Hsu et al., 2015; Iliopoulos et al., 2011) . Treatment of breast cancer cells with IL-6 antibody abolished STAT3 phosphorylation (Deshmukh et al., 2015) ; targeting IL-6/STAT3 signaling pathway might be an effective approach for breast cancer treatment (Markkula et al., 2014; Niu et al., 2015) .
In the present experiment, breast CSCs were exposed to EsA in vitro and in vivo; protein expressions of IL-6, phosphorylated STAT3 (Tyr705), and STAT3 (Ser727) in EsA-treated breast CSCs and tumor 
| CONCLUSION
In summary, EsA possesses the potential to suppress breast CSC growth in vitro and in vivo through stemness attenuation and apoptosis induction by abating IL-6/STAT3 signaling pathway; it might serve as a novel anticancer agent to kill CSCs for human breast cancer treatment and/or prevention and need to be studied further. 
